Efficacy of neoadjuvant atezolizumab treatment in patients with advanced urothelial bladder cancer according to the BASQ classification: a study protocol for an open-label, two-cohort, phase II trial

INTRODUCTION: Atezolizumab is a programmed death ligand-1 inhibitor for urothelial bladder cancer treatment. Atezolizumab has become the standard therapy for patients with urothelial bladder cancer who are not responding to cisplatin-based chemotherapy and is also used as a first-line treatment in c...

Full description

Saved in:
Bibliographic Details
Published in:BMJ Open
Main Authors: Yuk, Hyeong Dong, Jeong, Chang Wook, Kwak, Cheol, Kim, Hyeon, Moon, Kyung Chul, Ku, Ja Hyeon
Format: Artigo
Language:Inglês
Published: BMJ Publishing Group 2020
Subjects:
Urology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7566723/
https://ncbi.nlm.nih.gov/pubmed/33060077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2019-035530
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items